Inventurus Knowledge Solutions Reports Strong Q1 FY27 Results, Driven by 21% Revenue Growth and 28% PAT Increase
Inventurus Knowledge Solutions Limited (IKS) has reported robust financial results for the first quarter of fiscal year 2027, ending June 30, 2026. The global healthcare technology company delivered significant growth in revenue and profit, underscoring the resilience of its business model through providing technology-enabled solutions to improve operational efficiency and care delivery across various healthcare settings.IKS partners with health systems, physician groups, specialty practices, and community hospitals, utilizing the IKS Health platform. This platform integrates agentic AI workflows with human expertise to facilitate smarter operations and financially sustainable growth throughout the care journey.
Citing strong client trust and operational efficiency, Sachin K. Gupta, Founder and Global CEO of IKS Health, stated that the quarter's results demonstrate the resilience of the company. He noted that their momentum builds upon a decade of profitable growth, which has been marked by an impressive 46% PAT CAGR. Furthermore, he highlighted the acquisition of TruBridge as a milestone that expands capabilities and strengthens service delivery to rural and community health systems.
Nithya Balasubramanian, Group CFO, added that the company closed Q1 FY27 with robust financial results, achieving 21% year-over-year revenue growth and a 28% year-over-year increase in PAT. She attributed these outcomes to a focus on cost discipline, platform scalability, and capital efficiency, emphasizing the priority of protecting margins while making prudent investments for long-term value.
Key Financial Performance Highlights (Q1 FY27)
The company’s financial performance for the quarter ended June 30, 2026, is detailed in the table below:| Metric | Value | Year-over-Year Growth |
|---|---|---|
| Revenue | INR 8,936 Mn | 20.7% |
| EBITDA | INR 2,949 Mn (33% of revenue) | 24% |
| PAT | INR 1,937 Mn (21.7% of revenue) | 27.8% |
| Adjusted PAT | INR 2,153 Mn (24.1% of revenue) | 28.0% |
Recognition and Awards
IKS Health received several notable industry recognitions in the reporting period:- A U.S. patent was granted for its proprietary Engagement Learning Engine, which uses 'Awareness-Ability-Willingness' (AAW) behavioral modeling to enhance patient engagement and scheduling through solutions like MyCareHub.
- The company’s CEO, Sachin K. Gupta, received the 2026 Titan 100 award for Best CFO & Finance Strategy Excellence.
- IKS Health was recognized with the Best CFO in Healthcare Award, given to Nithya Balasubramanian, Whole-time Director and Group CFO.
- The company earned recognition at the FE HR Awards 2026 for Excellence in Onboarding and Role Enablement.
- IKS received the American Medical Group Association (AMGA) Distinguished Corporate Partner Award 2026.
Company Overview
IKS Health’s Care Enablement platform is designed to reduce the administrative, clinical, and operational burdens that impede healthcare progression. By integrating AI and agentic workflows with human expertise, IKS aims to enable smarter operations, better outcomes, and financially sustainable growth throughout the care journey. The company partners with major health systems, physician groups, and specialty practices across the United States.IKS Stock Price Movement
On Wednesday, Inventurus Knowledge Solutions Limited shares edged higher to close at ₹1877.7, gaining 2.06% in the previous session. The stock saw a total traded volume of 82,155 shares during the market day.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.